| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 04/29/2010 | US20100105769 pharmaceutical composition containing daurinol for the prevention and treatment of cancers |
| 04/29/2010 | US20100105767 Compounds, compositions and methods |
| 04/29/2010 | US20100105764 Use |
| 04/29/2010 | US20100105745 Suppression of cancer and method for evaluating anticancer agent based on the effect of inhibiting gsk3 beta |
| 04/29/2010 | US20100105726 Imidazole derivatives that induce apoptosis and their therapeutic uses |
| 04/29/2010 | US20100105723 5-PHENYL-6-PYRIDIN-4-YL-1,3-DIHYDRO-2H-IMIDAZO[4,5-b]PYRIDIN-2-ONE DERIVATIVES USEFUL AS A2B ADENOSINE RECEPTOR ANTAGONISTS |
| 04/29/2010 | US20100105721 IMIDAZO[1,2-a]PYRIDINE DERIVATIVES: PREPARATION AND PHARMACEUTICAL APPLICATIONS |
| 04/29/2010 | US20100105712 Chemical compounds |
| 04/29/2010 | US20100105700 Decahydro-1h-indenoquinolinone and decahydro-3h-cyclopentaphenanthridinone cyp17 inhibitors |
| 04/29/2010 | US20100105698 Therapeutic Methods and Compounds |
| 04/29/2010 | US20100105692 Dipterinyl Calcium Pentahydrate (DCP) and Therapeutic Methods Based Thereon |
| 04/29/2010 | US20100105689 Novel 1,4- and 1,5-diarylsubstituted 1,2,3-triazoles useful as potassium channel modulators |
| 04/29/2010 | US20100105683 Compounds useful for inhibiting chk1 |
| 04/29/2010 | US20100105682 Cyclopropyl-piperazine compounds as calcium channel blockers |
| 04/29/2010 | US20100105674 Chemical Compounds |
| 04/29/2010 | US20100105668 Quinazoline derivatives |
| 04/29/2010 | US20100105667 Quinoxaline- and Quinoline-Carboxamide Derivatives |
| 04/29/2010 | US20100105665 Renin inhibitors |
| 04/29/2010 | US20100105656 Triazolopyrazine derivatives |
| 04/29/2010 | US20100105655 Novel compounds 515 |
| 04/29/2010 | US20100105626 Novel Analogues of Antimicrobial and Anticancer Peptide Synthesized and Produced from Gaegurin 5 |
| 04/29/2010 | US20100105618 Non-Natural Recombinant Gelatins with Enhanced Functionality |
| 04/29/2010 | US20100105610 Methods of Inhibiting Tumor Cell Aggressiveness Using the Microenvironment of Human Embryonic Stem Cells |
| 04/29/2010 | US20100105122 Oncolytic Viruses as Phenotyping Agents for Neoplasms |
| 04/29/2010 | US20100105121 Nucleic acid molecules encoding transmembrane serine proteases, the encoded proteins and methods based thereon |
| 04/29/2010 | US20100104662 Composition and methods for modulating cell proliferation and cell death |
| 04/29/2010 | US20100104661 Discontinuous methods of treating cancer |
| 04/29/2010 | US20100104660 Composition and method for treating tumor |
| 04/29/2010 | US20100104659 Benzopyranopyrazoles |
| 04/29/2010 | US20100104655 Therapeutic Polymeric Nanoparticles Comprising Vinca Alkaloids and Methods of Making and Using Same |
| 04/29/2010 | US20100104647 Hollow microparticles |
| 04/29/2010 | US20100104645 Methods for the preparation of targeting agent functionalized diblock copolymers for use in fabrication of therapeutic targeted nanoparticles |
| 04/29/2010 | US20100104628 method of treating neuroblastoma |
| 04/29/2010 | US20100104601 Treatment of immune disease by mucosal delivery of antigents using genetically modified lactobacillus |
| 04/29/2010 | US20100104589 Immunoconjugates with an Intracellularly-Cleavable Linkage |
| 04/29/2010 | US20100104586 Treatment of Carcinomas with a Combination of EGF-Pathway and Telomerase Inhibitors |
| 04/29/2010 | US20100104584 Genes involved in mitochondrial biogenesis |
| 04/29/2010 | US20100104583 Gene Polymorphisms in VEGF and VEGF Receptor 2 as Markers for Cancer Therapy |
| 04/29/2010 | US20100104582 CD200 and its receptor, CD200R, modulate bone mass via the differentiation of osteoclasts |
| 04/29/2010 | US20100104578 Method and composition for treatment of neoplasms |
| 04/29/2010 | US20100104574 Frizzled-Binding Agents and Uses Thereof |
| 04/29/2010 | US20100104572 Methods for screening for therapeutic molecules and use of the molecules therefrom |
| 04/29/2010 | US20100104567 Pharmaceutical composition |
| 04/29/2010 | US20100104566 Antitumor combination comprising a morpholinyl anthracycline and an antibody |
| 04/29/2010 | US20100104565 Combinations comprising dmxaa for the treatment of cancer |
| 04/29/2010 | US20100104564 Altered Antibody Fc Regions and Uses Thereof |
| 04/29/2010 | US20100104563 Interleukin-18 specific immunoglobulins for treatment and prevention of autoimmune, respiratory, reproductive, heart, connective tissue, liver, bone and arthritic disorders |
| 04/29/2010 | US20100104559 Us cip-compositions and methods for modulating responses mediated or associated with btla activity |
| 04/29/2010 | US20100104556 Epitope-tag for surface-expressed proteins and uses thereof |
| 04/29/2010 | US20100104553 Antibodies and methods for making and using them |
| 04/29/2010 | US20100104515 Use of alpha-hydroxy carbonyl compounds as reducing agents |
| 04/29/2010 | US20100104511 Methods and compositions using chelator-antibody conjugates |
| 04/29/2010 | US20100104510 Selenocysteine mediated hybrid antibody molecules |
| 04/29/2010 | US20100104507 Use of sterically stabilized cationic liposomes to efficiently deliver cpg oligonucleotides in vivo |
| 04/29/2010 | DE4035442B4 Arzneimittel enthaltend als Wirkstoff R-α-Liponsäure A medicament comprising as an active ingredient R-α-lipoic acid |
| 04/29/2010 | DE102009004436A1 Verwendung einer Tirucallensäure, einer Lupansäure oder einer Robursäure als Arzneimittel Using a Tirucallensäure, a Lupansäure or Robur acid as a drug |
| 04/29/2010 | DE10085492B4 Antimonocytenaktivität von extrakten von Betelpfefferblättern Antimonocytenaktivität of extracts of Betelpfefferblättern |
| 04/29/2010 | CA2741428A1 Azaindole derivatives |
| 04/29/2010 | CA2741399A1 Rab6kifl/kif20a epitope peptide and vaccines containing the same |
| 04/29/2010 | CA2741312A1 Combination therapy with peptide epoxyketones |
| 04/29/2010 | CA2741189A1 Transition metal complexes of bis[thiohydrazide amide] compounds |
| 04/29/2010 | CA2740857A1 Composition for targeting dendritic cells |
| 04/29/2010 | CA2740810A1 Phenanthroindolizidine compound and nf.kappa.b inhibitor containing same as active ingredient |
| 04/29/2010 | CA2740807A1 Phenanthroindolizidine derivative and nf.kappa.b inhibitor containing same as active ingredient |
| 04/29/2010 | CA2740616A1 Sulphone-substituted anilinopyrimidine derivatives as cdk inhibitors, their preparation and use as medicaments |
| 04/29/2010 | CA2740313A1 Crystalline forms of (r) -5- [3-chloro-4- ( 2, 3-dihydroxy-propoxy) -benz [z] ylidene] -2- ( [z] -propylimino) -3-0-tolyl-thiazolidin-4-one |
| 04/29/2010 | CA2739739A1 Sulfoximine-substituted anilino-pyrimidine derivatives as cdk inhibitors, production and use thereof as medicinal products |
| 04/29/2010 | CA2735956A1 Phosphodiestarase inhibitors |
| 04/28/2010 | EP2180044A1 Antibody glycosylation variants having increased anti-body-dependent cellular cytotoxicity |
| 04/28/2010 | EP2180007A2 Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity |
| 04/28/2010 | EP2180003A1 Preparation of ibandronate trisodium |
| 04/28/2010 | EP2179999A1 Fused tricyclic compound having aldose reductase inhibitory activity |
| 04/28/2010 | EP2179993A1 Sulfoxide substituted aniline pyrimidine derivatives as CDK inhibitors, their manufacture and use as medicine |
| 04/28/2010 | EP2179992A1 Sulfon substituted aniline pyrimidine derivatives as CDK inhibitors, their manufacture and use as medicine |
| 04/28/2010 | EP2179991A1 Sulfoximine substituted aniline pyrimidine derivatives as CDK inhibitors, their manufacture and use as medicine |
| 04/28/2010 | EP2179745A1 Combinations comprising epothilones and pharmaceutical uses thereof |
| 04/28/2010 | EP2179730A1 Pharmaceuticals and methods for treating hypoxia and screening methods therefor |
| 04/28/2010 | EP2179040A2 Compositions and methods for treating tumors, fibrosis, and pulmonary alveolar proteinosis |
| 04/28/2010 | EP2178920A1 An anti-cancer cytotoxic monoclonal antibody |
| 04/28/2010 | EP2178919A1 An anti-cancer cytotoxic monoclonal antibody |
| 04/28/2010 | EP2178918A1 An anti-cancer cytotoxic monoclonal antibody |
| 04/28/2010 | EP2178916A1 Human antibodies to human cd20 and method of using thereof |
| 04/28/2010 | EP2178888A1 Proteasome inhibitors |
| 04/28/2010 | EP2178881A2 Novel 6-triazolopyridazinesulfanyl benzothiazole and benzimidazole derivatives, method for production thereof and application as medicaments and pharmaceutical compositions and novel use as met inhibitors |
| 04/28/2010 | EP2178879A2 6-cycloamino-s-(pyridazin-4-yl)imidazo[1,2-b]-pyridazine and derivatives thereof preparation and therapeutic application thereof |
| 04/28/2010 | EP2178875A1 Indolopyridines as inhibitors of the kinesin spindle protein (eg5 ) |
| 04/28/2010 | EP2178868A1 Bicyclic heteroaryl compounds and their use as kinase inhibitors |
| 04/28/2010 | EP2178866A2 Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases |
| 04/28/2010 | EP2178854A1 Lejimalid analoga and uses thereof |
| 04/28/2010 | EP2178840A1 Azabiphenylaminobenzoic acid derivatives as dhodh inhibitors |
| 04/28/2010 | EP2178563A2 Combination anti-cancer therapy comprising an inhibitor of both mtorc1 and mtorc2 |
| 04/28/2010 | EP2178557A1 Composition of tumour-associated peptides and related anti-cancer vaccine |
| 04/28/2010 | EP2178555A1 Albumin for treating cancer and a pharmaceutical composition comprising the combination of an anti-neoplastic agent and albumin |
| 04/28/2010 | EP2178551A1 Novel peptides with anti-tumor activity |
| 04/28/2010 | EP2178545A2 Fraction of melissa leaf extract having angiogenesis and mmp inhibitory activities, and composition comprising the same |
| 04/28/2010 | EP2178527A1 Method for activating regulatory t-cells |
| 04/28/2010 | EP1643989B1 Cis-imidazolines as mdm2 inhibitors |
| 04/28/2010 | EP1599228B1 Modified antibodies to prostate-specific membrane antigen and uses thereof |
| 04/28/2010 | EP1590321B1 Aryl alkyl carbamate derivatives production and use thereof in therapy |
| 04/28/2010 | EP1480650B1 Novel crystalline forms of the anti-cancer compound zd1839 |